skip to main content
10.1145/3510427.3510445acmotherconferencesArticle/Chapter ViewAbstractPublication PagesicbbbConference Proceedingsconference-collections
research-article

Investigating the Mechanism of Chemical Drugs on Neurodegenerative Diseases

Published: 03 March 2022 Publication History

Abstract

Neurodegenerative diseases are one of the most commonly seen diseases, especially among the elderly. AD and PD are by far the most common neurodegenerative diseases affecting around 50 million people worldwide. This number is estimated to be tripled to 14 million by 2060 as the world population continues to age. The number of individuals at risk of developing neurodegenerative diseases will also increase, particularly among the elderly. The neuropathological hallmarks of Alzheimer's Diseases (AD) are thought to be the formation of beta amyloid plaques, intracellular neurofibrillary tangles, which leads to loss of neurons and synapses. In contrast, the neuropathological finding for Parkinson's Diseases (PD) is the loss of dopamine producing neurons in the substantia nigra, resulting in loss of the ability of voluntary movements. This article aims to provide an overview of different types of treatments used for treating AD and PD. Drugs such as acetylcholinesterase inhibitors and NMDA antagonists are currently FDA approved medicines used to treat AD. Monoamine Oxidase B inhibitors, Levodopa and dopamine agonist are drugs prescribed to patients diagnosed with PD. In addition, music therapy, art therapy and orientation exercises are provided to patients alongside The drugs to slow down the cognition decline. However, those drugs usually are associated with side effects such as vomiting, diarrhea, headache and constipation. Therefore, better treatments are required to have more effective medicines with lower side effects to treat AD and PD.

References

[1]
Agyeman, A. and Ofori-Asenso, R. 2015. Perspective: Does personalized medicine hold the future for medicine?. Journal of Pharmacy and Bioallied Sciences, 7(3), 239.
[2]
Berman, T. and Bayati, Armin. 2018. December. What are neurodegenerative diseases and how do they affect the brain. Retrieved June 25, 2021, form https://kids.frontiersin.org/articles/10.3389/frym.2018.00070
[3]
Goedert M. 2015. Neurodegeneration. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science (New York, N.Y.) 349(6248), 1255555
[4]
DeTure, M. A and Dickson, D. W. 2019. The neuropathological diagnosis of Alzheimer's disease. Molecular neurodegeneration, 14(1), 32.
[5]
Tarawneh, R. and Holtzman, D. M. 2012. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harbor perspectives in medicine, 2(5), a006148.
[6]
Roberts, R. O., Knopman, D. S., Mielke, M. M., Cha, R. H., Pankratz, V. S., Christianson, T. J., Geda, Y. E., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Rocca, W. A. and Petersen, R. C. 2014. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology, 82(4), 317–325.
[7]
National Institute on Aging. 2021. Parkinson's Disease. Retrieved July 5, 2021 from https://www.nia.nih.gov/health/parkinsons-disease
[8]
Alexander G. E. 2004. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in clinical neuroscience, 6(3), 259–280.
[9]
Alzheimer's Society. 2021. Alzheimer's Society's view on demography. Retrieved 5 July, 2021, from https://www.alzheimers.org.uk/about-us/policy-and-influencing/what-we-think/demography
[10]
Qiu, C., Kivipelto, M. and Von Strauss, E. 2009. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in clinical neuroscience, 11(2), 111–128.
[11]
Parkinson's Foundation. 2021. Statistics. Retrieved July 6, 2021, from https://www.parkinson.org/Understanding-Parkinsons/Statistics
[12]
Mayeux, R. and Stern, Y. 2012. Epidemiology of Alzheimer disease. Cold Spring Harbor perspectives in medicine, 2(8), a006239.
[13]
Alzheimer. 2021. International work - Alzheimer. Retrieved July 24, 2021, from https://alzheimer.ie/creating-change/policy-on-dementia-in-ireland/international-work/
[14]
Yang, W., Hamilton, J., Kopil, C., Beck, J., Tanner, C., Albin, R., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P. and Thompson, T. 2020. Current and projected future economic burden of Parkinson's disease in the U.S. npj Parkinson's Disease, 6
[15]
Sun, X., Chen, W. and Wang, Y. 2015. β-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. Frontiers in Pharmacology, 6.
[16]
O'Brien, R. J. and Wong, P. C. 2011. Amyloid precursor protein processing and Alzheimer's disease. Annual review of neuroscience, 34, 185–204.
[17]
Spires-Jones, T. L. and Hyman, B. T. 2014. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron, 82(4), 756–771.
[18]
Smith, E. and Greenberg, S. 2009. β-Amyloid, Blood Vessels, and Brain Function. Stroke, 40(7), 2601-2606.
[19]
Drew, L. 2018. An age-old story of dementia. Nature, 559(7715), S2-S3.
[20]
Šimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., Wischik, C. and Hof, P. 2016. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 6(1), 6.
[21]
Wilkinson, D., Francis, P., Schwam, E. and Payne-Parrish, J. 2004. Cholinesterase Inhibitors Used in the Treatment of Alzheimer's Disease. Drugs & Aging, 21(7), 453-478.
[22]
Pope, C., Karanth, S. and Liu, J. 2005. Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of a common mechanism of action. Environmental Toxicology and Pharmacology, 19(3), 433-446.
[23]
Cacabelos R. 2007. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatric disease and treatment, 3(3), 303–333.
[24]
Mitra, A., n.d. Therapeutic Interventions in Alzheimer Disease.
[25]
Casey, D. A., Antimisiaris, D. and O'Brien, J. 2010. Drugs for Alzheimer's disease: are they effective?. P & T : a peer-reviewed journal for formulary management, 35(4), 208–211.
[26]
National Institute on Aging. 2021. How Is Alzheimer's Disease Treated?. Retrieved July 21, 2021, from https://www.nia.nih.gov/health/how-alzheimers-disease-treated
[27]
Colović, M. B., Krstić, D. Z., Lazarević-Pašti, T. D., Bondžić, A. M. and Vasić, V. M. 2013. Acetylcholinesterase inhibitors: pharmacology and toxicology. Current neuropharmacology, 11(3), 315–335.
[28]
Centerwatch.com. 2021. Namenda (memantine HCl). Retrieved July 8, 2021, from https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3864-namenda-memantine-hcl
[29]
Pubchem.ncbi.nlm.nih.gov. 2021. Levodopa. Retrieved July 8, 2021, from https://pubchem.ncbi.nlm.nih.gov/compound/Levodopa
[30]
nhs.uk. 2021. Parkinson's disease - Treatment. Retrieved July 9, 2021, from https://www.nhs.uk/conditions/parkinsons-disease/treatment/
[31]
Youdim M. B. 1986. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease. Journal of neural transmission. Supplementum, 22, 91–105.
[32]
En.m.wikipedia.org. 2021. Catechol-O-methyltransferase inhibitor - Wikipedia. Retrieved July 21, 2021, from https://en.m.wikipedia.org/wiki/Catechol-O-methyltransferase_inhibitor
[33]
Nguyen, T., Nguyen, T., Nguyen, T., Vo, T. and Vo, V. 2021. Advances in developing therapeutic strategies for Alzheimer's disease. Biomedicine & Pharmacotherapy, 139, 111623.
[34]
Cao, J., Hou, J., Ping, J. and Cai, D. 2018. Advances in developing novel therapeutic strategies for Alzheimer's disease. Molecular neurodegeneration, 13(1), 64.
[35]
Alzforum.org. 2021. LMTM | ALZFORUM. Retrieved July 9, 2021, from https://www.alzforum.org/therapeutics/lmtm
[36]
Alzheimer's Research UK. 2021. Behind the headlines: Is a new Alzheimer's treatment in sight? | Alzheimer's Research UK. Retrieved July 9, 2021, from https://www.alzheimersresearchuk.org/blog/behind-the-headlines-is-a-new-alzheimers-treatment-in-sight/
[37]
Agyeman, A. and Ofori-Asenso, R. 2015. Perspective: Does personalized medicine hold the future for medicine?. Journal of Pharmacy and Bioallied Sciences, 7(3), 239.
[38]
Vogenberg, F. R., Isaacson Barash, C., and Pursel, M. 2010. Personalized medicine: part 1: evolution and development into theranostics. P & T : a peer-reviewed journal for formulary management, 35(10), 560–576.
[39]
Meroua Daoudi, Souham Meshoul, and Fariza Tahi. 2019. "A Machine Learning Approach for Gene Regulatory Network Inference," International Journal of Bioscience, Biochemistry and Bioinformatics vol. 9, no. 2, 82-89
[40]
Devanshi D. Dave, Brajesh Kumar Jha. 2019. "Study of Calcium Distribution in Alzheimer's Disease Using Finite Element Technique," International Journal of Bioscience, Biochemistry and Bioinformatics vol. 9, no. 1, 35-41.

Recommendations

Comments

Information & Contributors

Information

Published In

cover image ACM Other conferences
ICBBB '22: Proceedings of the 2022 12th International Conference on Bioscience, Biochemistry and Bioinformatics
January 2022
142 pages
ISBN:9781450387385
DOI:10.1145/3510427
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]

Publisher

Association for Computing Machinery

New York, NY, United States

Publication History

Published: 03 March 2022

Permissions

Request permissions for this article.

Check for updates

Author Tags

  1. Alzheimer's diseases
  2. Parkinson's diseases
  3. mechanism of action of drugs

Qualifiers

  • Research-article
  • Research
  • Refereed limited

Conference

ICBBB '22

Contributors

Other Metrics

Bibliometrics & Citations

Bibliometrics

Article Metrics

  • 0
    Total Citations
  • 49
    Total Downloads
  • Downloads (Last 12 months)12
  • Downloads (Last 6 weeks)1
Reflects downloads up to 14 Jan 2025

Other Metrics

Citations

View Options

Login options

View options

PDF

View or Download as a PDF file.

PDF

eReader

View online with eReader.

eReader

HTML Format

View this article in HTML Format.

HTML Format

Media

Figures

Other

Tables

Share

Share

Share this Publication link

Share on social media